Shield Thera Regulatory News (STX)

Shield Therapeutics plc

("Shield" or the "Group")

Board change

London, UK, 7 November 2016. Shield Therapeutics plc (LSE:STX), a specialty pharmaceutical company focused on secondary care, announces that Richard Jones, Chief Financial Officer, will leave the Group in early 2017 to pursue a new opportunity. Until his departure Richard will continue as a Board member and Shield's Chief Financial Officer, with a focus on progressing key commercialisation workstreams as well as facilitating an orderly transition. A further announcement regarding the appointment of a new Chief Financial Officer will be made in due course.

Carl Sterritt, Chief Executive Officer of Shield Therapeutics, said: "Richard has helped build the Group from its inception as a small private company through to being listed on AIM. I would like to thank him for his significant contribution to Shield and wish him the best in his future endeavours as we continue to grow rapidly into a commercial-stage specialty pharmaceutical business with international operations."

Richard Jones added: "I have thoroughly enjoyed my six and a half years of service to Shield, working with Carl and the team, and I am very proud of what we have achieved. It is now time to apply my skills to a new challenge."

- Ends -

For further information please contact:

About Shield Therapeutics plc

Shield Therapeutics is a specialty pharmaceutical company focused on the commercialisation and development of late-stage, hospital-focused pharmaceuticals which address areas of unmet medical need. The Group has a marketed product, Feraccru®, for the treatment of iron deficiency anaemia (IDA) which has exclusive IP rights until 2034. In addition, the Group is developing PT20, a late-stage pharmaceutical for the treatment of systemic phosphate accumulation (hyperphosphatemia). Shield Therapeutics, headquartered in London, is listed on LSE's AIM under the ticker STX. For more information please visit www.shieldtx.com.